Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Apricus confirms strategy for fispemifene, following FDA guidance on enclomiphene

Dec. 3, 2015

Phase I trial results of T1D immunotherapy with autologous polyclonal Tregs

Dec. 3, 2015

Kamada provides update on alpha1-antitrypsin development in type 1 diabetes

Dec. 3, 2015

Novo Nordisk licenses antibodies targeting insulin receptor from XOMA

Dec. 2, 2015

Repros Therapeutics receives FDA complete response letter for enclomiphene

Dec. 2, 2015

HTIT licenses marketing rights to Oramed's oral insulin in China

Dec. 2, 2015

European Comission approves Horizon's Ravicti

Dec. 1, 2015

Chengdu Bestchiralbio announces DPP IV inhibitors

Dec. 1, 2015

Gene therapy that restores copper metabolism in model of Wilson disease granted E.U. orphan status

Nov. 30, 2015

PCSK9 vaccine reduces cholesterol and triglyceride levels in mice and monkeys

Nov. 30, 2015

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...